SGLT2 抑制剂减轻糖尿病中对比诱导的急性损伤:临床和实验证据
Mu-Chi Chung1,2,3,4,5, Yu-Teng Chang1,6, Yi-Jia Guo7
1Division of Nephrology, Department of Medicine, Taichung Veterans General Hospital, Taichung 407219, Taiwan.
International journal of molecular sciences
|February 27, 2026
概括
-葡萄糖共载体2抑制剂 (SGLT2i) 在2型糖尿病中经皮冠状动脉干预 (PCI) 后显著降低对比诱导的急性损伤 (CIAKI) 的风险. SGLT2i通过减少管状损伤和炎症酶激活来减轻损伤.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
背景情况:
- 对比诱导的急性损伤 (CIAKI) 是2型糖尿病 (T2DM) 患者进行皮肤冠状动脉干预 (PCI) 的重要并发症.
- -葡萄糖共运输体2抑制剂 (SGLT2i) 对CIAKI的潜在保护作用尚未得到充分证实.
研究的目的:
- 研究SGLT2抑制剂在接受PCI的T2DM患者中预防CIAKI的疗效.
- 用临床和实验模型阐明SGLT2抑制剂作用的潜在机制,以防止CIAKI.
主要方法:
- 一项全国性嵌套病例控制研究利用台湾国家医疗保险研究数据库分析了SGLT2i使用与PCI后透析风险之间的关联.
- 在体外研究中,研究了达帕格利弗洛辛对用胺醇治疗的HK-2细胞的影响.
- 在体内研究评估了DAPAGLIFLOZIN在暴露于IOPAMIDOL的糖尿病大鼠中的疗效.
主要成果:
- 使用SGLT2i显着与PCI后透析风险降低相关 (调整后OR为0.33,95%CI为0.14-0.76;p=0.0094).
- 在体外,达帕格利弗洛辛减轻了IOPAMIDOL诱导的细胞毒性和NLRP3炎症酶激活在HK-2细胞.
- 在糖尿病大鼠中,达帕格利弗洛辛改善了功能,减少了管管损伤,并抑制了由炎症酶驱动的炎症.
结论:
- SGLT2抑制剂在接受PCI的T2DM患者中显示出对CIAKI的保护作用.
- 保护机制包括减轻管状损伤和抑制炎症酶激活.
- 在这种高风险患者群体中,SGLT2i代表了CIAKI有前途的预防策略.
相关概念视频
Acute Kidney Injury IV: Diagnostic Studies and Prevention
387
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
387
Dipeptidyl Peptidase 4 Inhibitors
786
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
786
Acute Kidney Injury I: Introduction
917
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
917
Oral Hypoglycemic Agents: Biguanides and Glitazones
739
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
739
Acute Kidney Injury II: Pathophysiology
1.3K
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
1.3K
Acute Kidney Injury V: Interprofessional Care
407
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
407


